Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis

Objective Despite the fact that rituximab depletes B cells in all treated patients with RA, not all patients show a favourable clinical response. The goal of this study was to provide insight into pharmacological changes in peripheral blood that are associated with clinical response to rituximab. Methods Gene expression profiling was performed on peripheral blood RNA of 13 patients with RA (test group) using Illumina HumanHT beadchip microarrays. An independent group of nine patients was used for validation using TaqMan quantitative PCR. Clinical responder status was determined after 6 months using change in 28-joint Disease Activity Score (ΔDAS28) and European League Against Rheumatism (EULAR) response criteria. Significance analysis of microarrays and ontology analysis were used for data analysis and interpretation. Results Pharmacogenomic analyses demonstrated marked interindividual differences in the pharmacological responses at 3 and 6 months after start of treatment with rituximab. Interestingly, only differences in the regulation of type I interferon (IFN)-response genes after 3 months correlated with the ΔDAS28 response. Good responders (∆DAS>1.2; n=7) exhibited a selective increase in the expression of type I IFN-response genes, whereas this activity was unchanged or hardly changed in non-responders (∆DAS<1.2; n=6) (p=0.0040 at a cut-off of 1.1-fold induction). Similar results were obtained using EULAR response criteria. These results were validated in an independent cohort of nine patients (five non-responders and four responders, p=0.0317). Conclusions A good clinical response to rituximab in RA is associated with a selective drug-induced increase in type I IFN-response activity in patients with RA. This finding may provide insight in the biological mechanism underlying the therapeutic response to rituximab.

[1]  S. Akira,et al.  Toll-like receptors and innate immunity , 2006, Journal of Molecular Medicine.

[2]  V. Pascual,et al.  Dendritic cells control B cell growth and differentiation. , 2005, Current directions in autoimmunity.

[3]  M. Leandro,et al.  B lymphocyte depletion in rheumatoid arthritis: targeting of CD20. , 2005, Current directions in autoimmunity.

[4]  P. Tak,et al.  Interferon-β for treatment of rheumatoid arthritis? , 2002, Arthritis research.

[5]  A. Syvänen,et al.  A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5 , 2008, Human molecular genetics.

[6]  W. B. van den Berg,et al.  Local activation of STAT-1 and STAT-3 in the inflamed synovium during zymosan-induced arthritis: exacerbation of joint inflammation in STAT-1 gene-knockout mice. , 2004, Arthritis and rheumatism.

[7]  C. Wijbrandts,et al.  Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood. , 2010, Arthritis and rheumatism.

[8]  C. Gordon,et al.  Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. , 2010, Arthritis and rheumatism.

[9]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Wijbrandts,et al.  Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. , 2010, Rheumatology.

[11]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[12]  P. Tak,et al.  The relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis , 2010 .

[13]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[14]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[15]  M. Feldmann,et al.  Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics , 2008, Immunological reviews.

[16]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Kutty Selva Nandakumar,et al.  Stromal cells and osteoclasts are responsible for exacerbated collagen-induced arthritis in interferon-beta-deficient mice. , 2005, Arthritis and rheumatism.

[19]  Michael H Weisman,et al.  New therapies for treatment of rheumatoid arthritis , 2007, The Lancet.

[20]  Marta E Alarcón-Riquelme,et al.  A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus , 2006, Nature Genetics.

[21]  L. Ivashkiv,et al.  TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon–response genes , 2008, Nature Immunology.

[22]  V. Pascual,et al.  Cross-regulation of TNF and IFN-¿ in autoimmune diseases , 2005 .

[23]  P. Emery,et al.  Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis , 2006, Expert opinion on pharmacotherapy.

[24]  R. Caporali,et al.  Long term treatment of rheumatoid arthritis with rituximab. , 2009, Autoimmunity reviews.

[25]  D. Athanazio,et al.  NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis , 2009, Rheumatology International.

[26]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. Firestein.  Evolving concepts of rheumatoid arthritis , 2003, Nature.

[28]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[29]  P. Emery,et al.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. , 2006, Arthritis and rheumatism.

[30]  Virginia Pascual,et al.  Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. , 2003, Immunity.

[31]  Koen Vos,et al.  Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. , 2010, Arthritis and rheumatism.

[32]  B. Dijkmans,et al.  Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment , 2010, Arthritis research & therapy.

[33]  V. Pascual,et al.  Cross-regulation of TNF and IFN-alpha in autoimmune diseases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  C. Verweij.  Predicting the future of anti-tumor necrosis factor therapy , 2009, Arthritis research & therapy.

[35]  Zlatko Trajanoski,et al.  CARMAweb: comprehensive R- and bioconductor-based web service for microarray data analysis , 2006, Nucleic Acids Res..

[36]  P. Tak,et al.  Interferon-beta for treatment of rheumatoid arthritis? , 2002 .

[37]  D. Hilbert,et al.  Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. , 2006, Arthritis and rheumatism.

[38]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[39]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[40]  C. Wijbrandts,et al.  Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients , 2007, Annals of the rheumatic diseases.

[41]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[42]  B. Dijkmans,et al.  Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. , 2004, Arthritis and rheumatism.